

## Special Issue

# Radioembolization for Hepatocellular Carcinoma

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Transarterial radioembolization (TARE), in which beta-emitting yttrium 90-loaded microspheres are injected intra-arterially into the tumor feeding artery, has been a well-established treatment option for HCC. TARE can be used as a palliative or curative treatment option depending on the stage and pattern of HCC and the dose used. In this Special Issue, we welcome original research and review articles focused on different aspects of TARE when used in the treatment of HCC. These topics can include dosimetry for TARE, advanced imaging techniques used for dose calculation, the combination of TARE with other locoregional or systemic treatments, genetic factors influencing responses after TARE, immunological aspects of TARE, adjuvant treatments that improve the efficacy of TARE, surgical resection after TARE, and portal vein embolization using TARE, to name a select few.

---

### Guest Editor

Dr. Hooman Yarmohammadi

Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA

---

### Deadline for manuscript submissions

closed (10 February 2025)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/168372](https://mdpi.com/si/168372)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
currentoncology](https://mdpi.com/journal/currentoncology)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)